Stockscreener 앱 받기
2.11
2.31%
-0.05
전일 마감가:
$2.16
열려 있는:
$2.14
하루 거래량:
20,723
Relative Volume:
0.03
시가총액:
$181.03M
수익:
$47.04M
순이익/손실:
$-63.98M
주가수익비율:
-2.6166
EPS:
-0.8064
순현금흐름:
$-34.39M
1주 성능:
-5.80%
1개월 성능:
+19.89%
6개월 성능:
-6.43%
1년 성능:
-20.08%
1일 변동 폭
$2.14
$2.18
1주일 범위
$2.04
$2.59
52주 변동 폭
$1.29
$3.5107
Innate Pharma Adr Stock (IPHA) Company Profile
IPHA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
2.14 | 181.03M | 47.04M | -63.98M | -34.39M | -0.8064 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.44 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
696.36 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
616.37 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.03 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
267.79 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-09-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-12-15 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-24 | 개시 | Goldman | Neutral |
Innate Pharma Adr 주식(IPHA)의 최신 뉴스
Innate Pharma shares retain Buy rating on long-term strategy - Investing.com
Nebius Group N.V (NASDAQ: NBIS)’s Upward Trend Continues - Stocks Register
Earnings call: Innate Pharma Q3 2024 results highlight oncology pipeline - Investing.com
Earnings call: Innate Pharma focuses on advancing cancer therapies - Investing.com
Earnings call: Innate Pharma focuses on advancing cancer therapies By Investing.com - Investing.com UK
Earnings call: Innate Pharma reports progress in drug development - Investing.com India
Earnings call: Innate Pharma reports progress in oncology pipeline - Investing.com
Contrast Security Introduces Application Detection and Response (ADR) to Identify and Block Attacks and Zero Days on Applications in Production - Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286 - Business Wire
Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities News
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
IPHA stock surges on upcoming presentation for AstraZeneca-partnered asset - Seeking Alpha
The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger - Yahoo Finance
Innate Pharma Adr (IPHA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.31%
0.86%
자본화:
|
볼륨(24시간):